English 
Spanish 
Lower Risk of Dementia with AS01-Adjuvanted Vaccination against Shingles and Respiratory Syncytial Virus Infections
These are results from propensity-score matched cohort studies with 436,788 individuals. They found that, both the AS01-adjuvanted shingles and respiratory syncytial virus (RSV) vaccines, individually or combined, were associated with reduced 18-month risk of dementia. No difference was observed between the two AS01-adjuvanted vaccines, suggesting that the AS01 adjuvant itself plays a direct role in lowering dementia risk.
Influenza Vaccination Reduces Dementia risk: A Systematic Review and Meta-analysis
This review references a number of human studies and animal models that suggest that getting the influenza vaccine reduces the risk of dementia. The review states evidence is limited, but in nine studies including 292,157 older participants, influenza vaccination decreased the risk of dementia. Results were not affected by potential confounders.
Association of SARS-CoV-2 With Health-related Quality of Life 1 Year After Illness Using Latent Transition Analysis
Results come from a prospective, multicenter, longitudinal registry study where patients were enrolled from December 2020 through August 2022 and completed three-month follow-up assessments until 12 months after enrollment. Participants were adults (≥18 years) with acute symptoms suggestive of COVID-19 who received a Food and Drug Administration–approved SARS-CoV-2 test. There were 1,096 (75%) COVID+ and 371 (25%) COVID−. Four distinct well-being classes emerged: optimal overall, poor mental, poor physical, and poor overall HRQoL. COVID+ participants were more likely to return to the optimal HRQoL class compared to COVID− participants. The most substantial transition from poor physical to optimal HRQoL occurred by three months, whereas movement from poor mental to optimal HRQoL occurred by nine months. In adults with COVID-19–like illness, COVID+ participants demonstrated meaningful recovery in their physical HRQoL by three months after infection, but mental HRQoL took longer to improve. Suboptimal HRQoL at three to 12 months after infection remained in approximately 20%.
Remdesivir and Risk of Multi-systemic Long-term Sequelae Following COVID-19 Hospitalization
This study looks at ability to prevent PASC with early treatment with remdesivir. 30,175 COVID-19 hospitalizations were included in the cohort for evaluating risk of long-term sequelae; 37.6% (11,353/30,175) received remdesivir. 88.9% of the cohort were fully-vaccinated, and 60.5% had received a booster dose; 77.4% were infected during Omicron. Risk of long-term new-onset diagnoses across cardiovascular, neurological, respiratory and autoimmune systems (any long-term diagnosis), up to 300 days post-COVID-19-hospitalization was not significantly different in the remdesivir-treated group, versus untreated individuals.
Situation Dashboards
World Health Organization (WHO)
Johns Hopkins University (JHU)
COVID-19 in US and Canada
